Free · No account required · Powered by AI across the world's largest grants + funders database
Currently focused on US federal, state, and foundation grants.
NIH Common Fund PRIMED-AI (anticipating NOFO) is sponsored by National Institutes of Health (NIH) Common Fund. Upcoming funding for AI tools integrating imaging and health data for personalized medicine—could be adapted for AI-assisted flexibility or massage assessment.
Official opportunity description and requirements excerpt:
Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) | NIH Common Fund An official website of the United States government Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. National Institutes of Health Division of Program Coordination Planning and Strategic Initiatives (DPCPSI) Search the Common Fund Website test Acute To Chronic Pain Signatures (A2CPS) Bridge to Artificial Intelligence (Bridge2AI) Cellular Senescence Network (SenNet) Common Fund Data Ecosystem (CFDE) Complement Animal Research In Experimentation (Complement-ARIE) Gabriella Miller Kids First Pediatric Research Program (Kids First) Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) High-Risk, High-Reward Research (HRHR) The Human BioMolecular Atlas Program (HuBMAP) Molecular Transducers of Physical Activity in Humans (MoTrPAC) Nutrition for Precision Health, powered by the All of Us Research Program Precision Medicine with AI (PRIMED-AI) Replication to Enhance Research Impact Initiative Somatic Cell Genome Editing (SCGE) Somatic Mosaicism Across Human Tissues (SMaHT) Stimulating Peripheral Activity to Relieve Conditions (SPARC) Transformative High Resolution Cryo-Electron Microscopy (CryoEM) Transformative Research to Address Health Disparities (THD) Advancing Health Communication Science and Practice Big Data to Knowledge (BD2K) Bioinformatics and Computational Biology Bridging Interventional Development Gaps (BrIDGs) Building Blocks, Biological Pathways and Networks (BBPN) Community Partnerships to Advance Science for Society (ComPASS) Clinical Research Policy Analysis and Coordination (CRpac) Clinical and Translational Science Awards (CTSAs) Extracellular RNA Communication (ExRNA) Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Genotype-Tissue Expression (GTEx) Healthcare Systems Research (HCS) Collaboratory Human Microbiome Project (HMP) Illuminating the Druggable Genome (IDG) Interdisciplinary Research (IR) Knockout Mouse Phenotyping Program (KOMP2) Library of Integrated Network-based Cellular Signatures (LINCS) Molecular Libraries and Imaging National Electronics Clinical Trials and Research (NECTAR) New Models of Data Stewardship (NMDS) NIH Medical Research Scholars Program (MRSP) Patient-Reported Outcomes Measurement Information System (PROMIS) Protein Capture Reagents Program (PCRP) Regenerative Medicine Program (RMP) Science of Behavior Change (SOBC) Single Cell Analysis Program (SCAP) Strengthening the Biomedical Research Workforce Undiagnosed Diseases Network (UDN) Sex As a Biological Variable Administrative Supplements Evaluation Report Library Congressional Budget Requests Office of Strategic Coordination Internships with Common Fund Programs Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Precision Medicine With AI: Integrating Imaging With Multimodal Data (PRIMED-AI) The NIH Common Fund’s Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) program will combine clinical imaging
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH) Common Fund” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) | NIH Common Fund An official website of the United States government Official websites use . gov A . gov website belongs to an official government organization in the United States.
Secure . gov websites use HTTPS ) or https:// means you’ve safely connected to the . gov website.
Share sensitive information only on official, secure websites.
National Institutes of Health Division of Program Coordination Planning and Strategic Initiatives (DPCPSI) Search the Common Fund Website test Acute To Chronic Pain Signatures (A2CPS) Bridge to Artificial Intelligence (Bridge2AI) Cellular Senescence Network (SenNet) Common Fund Data Ecosystem (CFDE) Complement Animal Research In Experimentation (Complement-ARIE) Gabriella Miller Kids First Pediatric Research Program (Kids First) Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) High-Risk, High-Reward Research (HRHR) The Human BioMolecular Atlas Program (HuBMAP) Molecular Transducers of Physical Activity in Humans (MoTrPAC) Nutrition for Precision Health, powered by the All of Us Research Program Precision Medicine with AI (PRIMED-AI) Replication to Enhance Research Impact Initiative Somatic Cell Genome Editing (SCGE) Somatic Mosaicism Across Human Tissues (SMaHT) Stimulating Peripheral Activity to Relieve Conditions (SPARC) Transformative High Resolution Cryo-Electron Microscopy (CryoEM) Transformative Research to Address Health Disparities (THD) Advancing Health Communication Science and Practice Big Data to Knowledge (BD2K) Bioinformatics and Computational Biology Bridging Interventional Development Gaps (BrIDGs) Building Blocks, Biological Pathways and Networks (BBPN) Community Partnerships to Advance Science for Society (ComPASS) Clinical Research Policy Analysis and Coordination (CRpac) Clinical and Translational Science Awards (CTSAs) Extracellular RNA Communication (ExRNA) Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Genotype-Tissue Expression (GTEx) Healthcare Systems Research (HCS) Collaboratory Human Microbiome Project (HMP) Illuminating the Druggable Genome (IDG) Interdisciplinary Research (IR) Knockout Mouse Phenotyping Program (KOMP2) Library of Integrated Network-based Cellular Signatures (LINCS) Molecular Libraries and Imaging National Electronics Clinical Trials and Research (NECTAR) New Models of Data Stewardship (NMDS) NIH Medical Research Scholars Program (MRSP) Patient-Reported Outcomes Measurement Information System (PROMIS) Protein Capture Reagents Program (PCRP) Regenerative Medicine Program (RMP) Science of Behavior Change (SOBC) Single Cell Analysis Program (SCAP) Strengthening the Biomedical Research Workforce Undiagnosed Diseases Network (UDN) Sex As a Biological Variable Administrative Supplements Evaluation Report Library Congressional Budget Requests Office of Strategic Coordination Internships with Common Fund Programs Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Precision Medicine With AI: Integrating Imaging With Multimodal Data (PRIMED-AI) The NIH Common Fund’s Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) program will combine clinical imaging with other types of health data (“multimodal data”) to develop innovative artificial intelligence (AI)-powered clinical decision support (CDS) tools to enable new personalized medicine strategies.
Based on current listing details, eligibility includes: Nonprofit organizations, institutions, government. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
This funding opportunity seeks to enhance operations of a Novel Psychoactive Substance Discovery, Education, and Reporting Institute (NPS Discovery) to rapidly identify and report newly emerging opioids, stimulants, and other drugs which may cause intoxication, impairment, or other adverse effects. Funding Opportunity Number: O-NIJ-2025-172538. Assistance Listing: 16.560. Funding Instrument: CA. Category: ST. Award Amount: Up to $2M per award.
Translating Disruptive New Approach Methodologies (NAMs) into Practice is sponsored by European Commission — Horizon Europe. Expected Impact: This Challenge supports ambitions to maintain and strengthen the health sector in Europe. It will: Accelerate the development and validation of disruptive NAMs for biomedical applications, including medicinal products and medical technologies Support regulatory innovation by providing evidence-based recommendations for the assessment of safety, efficacy, and quality of human health products using NAMs. Enable citizens to benefit from novel technologies that have been assessed through rigorous NAMs that have been validated to can predict potential effects in humans, and Provide industry with a harmonised and standardised NAM-based assessment toolkit that is faster and more flexible. Objective: Specific Objectives This is a two-stage Challenge competition with the ultimate ambition to deliver robust, validated NAMs that constitute a representative model or prototype system i.e. achieve TRL 6 after Stage 2. Applicants should apply to Stage 1 only where there is an outlook of the potential impact in the longer term. Stage 1 – Solution validation and benchmarking Applicants should: Take forward preliminary engagement with regulatory authorities, notified bodies and industry stakeholders Map regulatory, clinical, standardisation (where applicable) and industrial needs, and use this to develop a roadmap for adoption Develop a methodology for performance assessment Deliver small-scale feasibility experiments or modelling Conduct initial performance benchmarking (human relevance, reproducibility, transferability of the approach) Assess ethical, data governance and scalability considerations, as applicable to the given NAM under development. The following milestones need to be achieved at the end of Stage 1: Evidence that the NAM is viable for human relevant biomedical innovation, and addresses the needs of the identified use cases, and Clear commitment from industrial end-users and a well-defined regulatory plan to further develop the NAM in Stage 2. Progress to Stage 2 will be contingent on delivering a full proposal which will be assessed alongside the milestones achieved under Stage 1. Stage 2 – Development and user testing Applicants selected for Stage 2 will further develop and validate a functional, scalable NAM prototype ready for regulatory, industrial, or clinical uptake. Activities must cover a number of the following elements: Benchmarking the NAMs against state-of-the-art animal models and/or human trials Demonstration in relevant application, such as disease modelling, or testing of medicinal products and medical technologies for safety, efficacy, or quality Organisation of consultation meetings/workshops with industrial end users, regulators, CROs (Contract Research Organisations), standard setting bodies or other relevant stakeholders to gather further needs and feedback Engagement with infrastructures for testing and data collection as testing and validation of the NAM outside the developer’s lab Development of regulatory-grade data packages suitable for submission to relevant agencies (e.g. EMA, FDA, OECD), and Documentation on scalability, standardisation, and potential barriers to uptake. During the project’s implementation phase, beneficiaries will be encouraged to consider using the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) of the European Commission’s Joint Research Centre for aspects of standardisation, automation and validation of in vitro methods. These facilities operate and provide support at the interface between pre-normative research, regulatory sciences and innovation. Scope: New Approach Methodologies (NAMs) have the potential to replace, reduce or refine animal use in the testing96 of medicinal products. Scientific progress in recent decades has delivered several animal-free NAMs that have the potential to transform how we understand human biology and assess the safety, efficacy, and quality testing in the health sector. However, a lack of knowledge, experi Programme areas: Additional EIC activities, The European Innovation Council (EIC), Innovative Europe Official opportunity description and requirements excerpt: EU Funding & Tenders Portal EU Funding & Tenders Portal * Results & Innovation support * SME Self-assessment tool Home Funding Calls for proposals Translating Disruptive New Approach Methodologies (NAMs) into Practice Translating Disruptive New Approach Methodologies (NAMs) into Practice * Conditions and documents EIC Advanced Innovation Challenge (HORIZON-EIC-2026-AIC) HORIZON-EIC HORIZON EIC Grants HORIZON Lump Sum Grant [HORIZON-AG-LS] 26 February 2026 17:00:00 Brussels time This Challenge supports ambitions to maintain and strengthen the health sector in Europe. It will: * Accelerate the development and validation of disruptive NAMs for biomedical applications, including medicinal products and medical technologies * Support regulatory innovation by providing evidence-based recommendations for the assessment of safety, efficacy, and quality of human health products using NAMs. * Enable citizens to benefit from novel technologies that have been assessed through rigorous NAMs that have been validated to can predict potential effects in humans, and * Provide industry with a harmonised and standardised NAM-based assessment toolkit that is faster and more flexible. This is a two-stage Challenge competition with the ultimate ambition to deliver robust, validated NAMs that constitute a representative model or prototype system i.e. achieve TRL 6 after Stage 2. Applicants should apply to Stage 1 only where there is an outlook of the potential impact in the longer term. **Stage 1 – Solution validation and benchmarking** * Take forward preliminary engagement with regulatory authorities, notified bodies and industry stakeholders * Map regulatory, clinical, standardisation (where applicable) and industrial needs, and use this to develop a roadmap for adoption * Develop a methodology for performance assessment * Deliver small-scale feasibility experiments or modelling * Conduct initial performance benchmarking (human relevance, reproducibility, transferability of the approach) * Assess ethical, data governance and scalability considerations, as applicable to the given NAM under development. The following milestones need to be achieved at the end of Stage 1: * Evidence that the NAM is viable for human relevant biomedical innovation, and addresses the needs of the identified use cases, and * Clear commitment from industrial end-users and a well-defined regulatory plan to further develop the NAM in Stage 2. Progress to Stage 2 will be contingent on delivering a full proposal which will be assessed alongside the milestones achieved under Stage 1. **Stage 2 – Development and user testing** Applicants selected for Stage 2 will further develop and validate a functional, scalable NAM prototype ready for regulatory, industrial, or clinical uptake. Activities must cover a number of the following elements: * Benchmarking the NAMs against state-of-the-art animal models and/or human trials Application snapshot: target deadline February 26, 2026; published funding information €12M total budget (~$13M USD) ; up to €300K per project ; ~10 grants expected; eligibility guidance Open to legal entities established in EU Member States and countries associated to Horizon Europe (including EEA/EFTA countries, and other associated third countries). Action type: HORIZON-EIC HORIZON EIC Grants. Additional conditions: "> General conditions 1. Admissibility Conditions: Proposal page limit and layout The call is open for submission by A single legal entity established in a Member State or an Associated Country (‘mono-beneficiary’) if you are a start-up, SME or research performing organisation (university, research or technology organisation, including teams, individual Principal Investigators and inventors). Larger companies (i.e. which do not qualify as SMEs) are not eligible to apply as a single legal... See the official call documentation on the F&T Portal for full eligibility criteria and participation rules. Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
Application snapshot: target deadline rolling deadlines or periodic funding windows; published funding information Varies; eligibility guidance Nonprofit organizations, institutions, government.
Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
CDS tools are designed to help healthcare providers make informed decisions about a patient’s care by pulling information from all forms of medical data, including imaging and all other health measures. These tools help clinicians make decisions more efficiently and in a more holistic way by providing evidence-based and patient-specific recommendations.
These recommendations are based on more information than a clinician could reasonably review during a single session with a patient. Ultimately, CDS tools improve patient outcomes and quality of care. AI is revolutionizing the development of CDS tools.
Increasingly powerful AI algorithms offer new opportunities to rapidly combine vast amounts of patient data, including clinical imaging, on an individual level. These advancements have the potential to empower CDS tools to be more robust, more accurate, and even more personalized.
Although clinical imaging plays a vital role in prediction, diagnosis, treatment, and outcome assessment, weaving together imaging with other health data during the development of AI-based CDS tools remains challenging.
The PRIMED-AI program will support the development and adoption of innovative, reliable, and cost-effective AI-based CDS tools that combine clinical imaging with other types of health data to enhance care for patients with wide-ranging health conditions. Accomplishing this goal will revolutionize the delivery of personalized medicine and substantially improve quality of health for the American people.
PRIMED-AI will be centered around the following four foundational components: (1) combining imaging and non-imaging data, (2) developing AI tools, (3) implementing these tools in the clinic, and (4) building trust and coordination amongst researchers, clinicians, and patients.
The program will bring together these groups to participate in the following efforts: Directly targeting specific, unmet clinical needs by supporting the creation of sophisticated AI models to aid clinical decision making for individual patients. Accelerating translation of AI-enabled, image-based, multimodal CDS tools into practical clinical use.
Empowering academic-industrial partnerships that will develop AI-based technologies that leverage multiple data types, with the goal of enhancing the commercialization potential of novel AI algorithms. Generating a validation framework for rigorous, impartial assessment of the overall dependability of AI models developed across the PRIMED-AI ecosystem and beyond.
Supporting software tool development to address anticipated needs in key areas, as well as the development of standardized processes to support this emerging field. Enhancing communication between physicians, scientists, and patients within the PRIMED-AI space. Creating a logistics center to maximize the impact of the program through administrative and evaluative support, as well as facilitation of strategic outreach and engagement.
To learn more about PRIMED-AI strategic planning activities, visit the strategic planning page . Learn more about the focus areas of PRIMED-AI funding opportunities by viewing their forecasts here . Funding opportunities and webinars are expected to be announced in early 2026.
On April 21, 2025, The NIH Council of Councils approved the concept of the NIH Common Fund's Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Program. Find out more by browsing the presentation slides , the program description , or by viewing the videocast . A complete summary of the Strategic Planning Workshop is available .
This page last reviewed on Frequently Asked Questions Freedom of Information Act Office of the Inspector General HHS Vulnerability Disclosure NIH... Turning Discovery Into Health ® National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892 U. S.
Department of Health and Human Services
© 2026 Granted AI